FimmCyte was founded in 2022 in Sweden with the mission to revolutionize women’s healthcare through immune-based therapies. Built on cutting-edge research from the Karolinska Institutet, the company focuses on developing the first disease-modifying treatment for endometriosis. Its lead therapy leverages the body’s immune system to selectively target the cells responsible for endometriotic lesions, a breakthrough that has already shown promising results in early preclinical studies. FimmCyte continues to advance its science with the goal of delivering a safe, effective, and long-needed solution for millions affected by endometriosis worldwide.